13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001779763
Total reported value
$874.7M
$874.7M
25 檔
28.4%
The Q3 2025 SEC filing reveals that Iron Triangle Partners LP held a total portfolio value of $874.7M, covering 25 public equity positions.
Iron Triangle Partners LP executed strategic sector rebalancing during Q3 2025, establishing 14 new positions while fully exiting 16 holdings and trimming 7 positions.
In terms of portfolio concentration, the top 5 core holdings (including CVS, DXCM, ABBV) accounted for 28.4% of total reported equity market value during Q3 2025.
Top New Position Initiated
CVS
市值: $60.2M
Top Position Liquidated / Trimmed
DVA
前期市值: $48.9M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CVS | Cvs Health CORP | Stock-Healthcare | 8.55% | -4.63% | +6.39% | |
| 2 | DXCM | Dexcom Inc | Stock-Healthcare | 8.13% | -8.13% | EXIT | |
| 3 | ABBV | Abbvie Inc | Stock-Healthcare | 6.60% | -6.60% | EXIT | |
| 4 | MDT | Medtronic plc | Stock-Healthcare | 6.14% | -6.14% | EXIT | |
| 5 | CRL | Charles River Laboratories | Stock-Healthcare | 5.96% | +2.70% | -16.25% | |
| 6 | LLY | Eli Lilly & Co | Stock-Healthcare | 5.38% | -1.07% | — | |
| 7 | BTSG | Brightspring Health Services | Stock-Other | 5.21% | -1.37% | +3.21% | |
| 8 | RGEN | Repligen CORP | Stock-Healthcare | 5.13% | +0.87% | — | |
| 9 | GKOS | Glaukos CORP | Stock-Healthcare | 3.98% | -3.98% | EXIT | |
| 10 | THC | Tenet Healthcare CORP | Stock-Healthcare | 3.97% | -3.97% | EXIT | |
| 11 | EXK | Exact Sciences CORP | Stock-Materials | 3.89% | -3.89% | EXIT | |
| 12 | ADPT | Adaptive Biotechnologies | Stock-Other | 3.87% | -3.87% | EXIT | |
| 13 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 3.81% | -3.81% | EXIT | |
| 14 | GH | Guardant Health Inc | Stock-Healthcare | 3.55% | -3.55% | EXIT | |
| 15 | BKD | Brookdale Senior Living Inc | Stock-Other | 3.42% | +0.89% | +66.96% | |
| 16 | CAH | Cardinal Health Inc | Stock-Healthcare | 3.08% | -3.08% | EXIT | |
| 17 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 2.81% | +2.87% | — | |
| 18 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 2.62% | -2.62% | EXIT | |
| 19 | WST | West Pharmaceutical Services | Stock-Healthcare | 2.61% | -2.61% | EXIT | |
| 20 | AHCO | Adapthealth CORP | Stock-Other | 2.45% | +0.52% | +0.21% | |
| 21 | VCYT | Veracyte Inc | Stock-Other | 2.37% | +2.35% | — | |
| 22 | AM6 | Amicus Therapeutics Inc | Stock-Other | 2.21% | -2.21% | EXIT | |
| 23 | DOCS | Doximity Inc-class A | Stock-Healthcare | 2.18% | +1.30% | -55.44% | |
| 24 | IDYA | Ideaya Biosciences Inc | Stock-Other | 1.04% | +0.81% | — | |
| 25 | ARGX | Argenx Se - Adr | Stock-Healthcare | 1.04% | -1.04% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | BTSG | Brightspring Health Services | +3.2% | +3.21% | Add |
| 2 | ADPT | Adaptive Biotechnologies | +1.4% | +21.73% | Trim |
| 3 | JAZZ | Jazz Pharmaceuticals plc | +0.3% | — | Add |
| 4 | ABBV | Abbvie Inc | +0.2% | -19.87% | Add |
| 5 | NBIX | Neurocrine Biosciences Inc | +0.1% | — | Trim |
| 6 | AHCO | Adapthealth CORP | -0.3% | +0.21% | Add |
| 7 | THC | Tenet Healthcare CORP | -0.5% | -27.66% | Trim |
| 8 | GH | Guardant Health Inc | -0.5% | +33.33% | Trim |
| 9 | DOCS | Doximity Inc-class A | -1.1% | -55.44% | Trim |
| 10 | ARGX | Argenx Se - Adr | -1.6% | -36.40% | Trim |
| 11 | CAH | Cardinal Health Inc | -3.4% | +31.12% | Trim |
| 12 | CVS | Cvs Health CORP | — | NEW | New buy |
| 13 | DXCM | Dexcom Inc | — | NEW | New buy |
| 14 | DVA | Davita Inc | — | EXIT | Sold out |
| 15 | MDT | Medtronic plc | — | NEW | New buy |
| 16 | CRL | Charles River Laboratories | — | NEW | New buy |
| 17 | LLY | Eli Lilly & Co | — | NEW | New buy |
| 18 | RGEN | Repligen CORP | — | NEW | New buy |
| 19 | TEVA | Teva Pharmaceutical-sp Adr | — | EXIT | Sold out |
| 20 | BSX | Boston Scientific CORP | — | EXIT | Sold out |
| 21 | GMED | Globus Medical Inc - A | — | EXIT | Sold out |
| 22 | GKOS | Glaukos CORP | — | NEW | New buy |
| 23 | PODD | Insulet CORP | — | EXIT | Sold out |
| 24 | AZNN | Astrazeneca Plc-spons Adr | — | EXIT | Sold out |
| 25 | EXK | Exact Sciences CORP | — | NEW | New buy |
| 26 | MDGL | Madrigal Pharmaceuticals Inc | — | NEW | New buy |
| 27 | ONC | Beone Medicines Ltd-adr | — | EXIT | Sold out |
| 28 | A | Agilent Technologies Inc | — | EXIT | Sold out |
| 29 | MMSI | Merit Medical Systems Inc | — | EXIT | Sold out |
| 30 | BKD | Brookdale Senior Living Inc | — | NEW | New buy |
| 31 | NVST | Envista Holdings CORP | — | EXIT | Sold out |
| 32 | WST | West Pharmaceutical Services | — | NEW | New buy |
| 33 | ALNY | Alnylam Pharmaceuticals Inc | — | EXIT | Sold out |
| 34 | VCYT | Veracyte Inc | — | NEW | New buy |
| 35 | TWST | Twist Bioscience CORP | — | EXIT | Sold out |
| 36 | AM6 | Amicus Therapeutics Inc | — | NEW | New buy |
| 37 | ISRG | Intuitive Surgical Inc | — | EXIT | Sold out |
| 38 | TECH | Bio-techne CORP | — | EXIT | Sold out |
| 39 | EHABUSD | Enhabit Inc | — | EXIT | Sold out |
| 40 | TXG | 10x Genomics Inc-class A | — | EXIT | Sold out |
| 41 | IDYA | Ideaya Biosciences Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Iron Triangle Partners LP reported a total U.S. public equity portfolio value of $874.7M across 25 disclosed positions in Q3 2025.
During Q3 2025, Iron Triangle Partners LP's top holdings by market value included CVS (8.6%)、DXCM (8.1%)、ABBV (6.6%). The largest single position, CVS, represented 8.6% of total portfolio value.
In Q3 2025, Iron Triangle Partners LP made 41 total portfolio adjustments, initiating 14 new buys, adding to 4 positions, trimming 7 holdings, and fully liquidating 16 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.